Objective
Cardiovascular disease (CVD) is a leading cause of death worldwide. Compelling evidence indicates that dyslipidemia represent a key risk factor for CVD. Among approved lipid-lowering agents, statins are the most effective therapy for CVD. However, a substantial portion of high-risk patients treated with statins fail to achieve target cholesterol levels required for preventing CVD. Thus, sufficiently efficacious and safe alternatives are urgently required. In addition, non-alcoholic fatty liver disease (NAFLD), the most frequent liver disease, contributes to dyslipidemia and accelerates CVD progression. However, limited therapeutic options are available for the treatment of NAFLD. Interestingly, the host group has developed a novel strategy of peptide-nuclear hormone conjugates that allows for peptide-mediated selective tissue targeting of nuclear hormones, which enables for synergistic benefits in target tissues while avoiding adverse effects in off-target tissues. The current project, aims to develop a novel poly-pharmaceutical therapy for the treatment of dyslipidemia and NAFLD by combining two key hormones in the control of lipid metabolism: glucagon and thyroid hormone (T3). To this end, the host group synthesized a series of glucagon-T3 conjugates to allow liver specific delivery of T3 aiming to reduce serum lipid levels and reverse hepatic steatosis, without causing adverse cardiovascular effects. During the implementation of this project the applicant will assess the in vivo efficacy of the conjugates in a series of rodent models of the metabolic syndrome, hypercholesterolemia and NAFLD. In addition, the applicant will characterize the molecular mechanisms by which the conjugates induce their metabolic benefits, while carefully assessing the potential adverse effects that the conjugates may cause in off-target tissues. This project may ultimately facilitate the discovery and the development of a novel and more effective therapy against dyslipidemia and NAFLD.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
- medical and health sciences clinical medicine cardiology cardiovascular diseases arteriosclerosis
- natural sciences biological sciences biochemistry biomolecules lipids
- medical and health sciences clinical medicine hepatology
- medical and health sciences basic medicine physiology homeostasis
- medical and health sciences health sciences nutrition obesity
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
MSCA-IF-EF-ST - Standard EF
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-MSCA-IF-2015
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
85764 Neuherberg
Germany
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.